Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial
Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
Sporn MB. Dichotomies in cancer research: some suggestions for a new synthesis. Nat Clin Pract Oncol 2006;3:364-73.
Sporn MB. Dichotomies in cancer research: some suggestions for a new synthesis. Nat Clin Pract Oncol 2006;3:364-73.
6
34047268764
The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, prevent lung cancer induced by vinyl carbamate in A/J mice
Liby K, Royce DB, Williams CR, et al. The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res 2007;67:2414-9.
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007; 7:357-69.
A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland
Liby K, Royce DB, Risingsong R, et al. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res 2007;13:6237-43.
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis
Liby K, Black CC, Royce DB, et al. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Mol Cancer Ther 2008;7:1251-7.
Novel synthetic oleanane triterpenoids: A series of highly active inhibitors of nitric oxide production in mouse macrophages
Honda T, Rounds BV, Bore L, et al. Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1999;9: 3429-34.
Honda T, Honda Y, Favaloro FG, Jr., et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12:1027-30.
Honda T, Honda Y, Favaloro FG, Jr., et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12:1027-30.
12
33846786713
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes
Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6:154-62.
Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells
Boehm MF, Zhang L, Zhi L, et al. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995;38:3146-55.
Design, synthesis, and biological evaluation of biotin conjugates of CDDO for the isolation of the protein targets
Honda T, Janosik T, Honda Y, et al. Design, synthesis, and biological evaluation of biotin conjugates of CDDO for the isolation of the protein targets. J Med Chem 2004;47:4923-32.
Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268
Liby K, Risingsong R, Royce DB, et al. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res 2008;14:4556-63.
The synthetic triterpenoid CDDO-imidazole blocks NF-κB activation through direct inhibition of IKK
Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid CDDO-imidazole blocks NF-κB activation through direct inhibition of IKK. Mol Cancer Ther 2006;5:3232-9.
